On Dec. 17, 2015, Merck announced that the U.S. Food and Drug Administration (FDA) approved Bridion® (sugammadex) Injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium) for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. The resources below provide CRNAs references and documents to support integration of sugammadex into practice.
- FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery, December 15, 2015
- AANA submits letter to the FDA encouraging the approval of sugammadex sodium injection for clinical use in the United States, November 5, 2015
AANA Practice Considerations
Visit AANALearn for professional development and continuing education opportunities:
- AANA Journal Course No. 35, Part 6: Residual Neuromuscular Blockade
- New Technological Modalities in Anesthesia
- Monitoring and Reversing Neuromuscular Block in the New Millennium
- Advanced Monitoring of Neuromuscular Block: State of the Art Assessment using Qualitative and Quantitative Measures
- 2013 AANA Journal Supplement: Deep neuromuscular blockade: Exploration and perspectives on multidisciplinary care.
- Abad-Gurumeta A, Ripolles-Melchor J, Casans-Frances R, et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia. Dec 2015;70(12):1441-1452.
- Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev. 2009(4):CD007362.
- Cheong SH, Ki S, Lee J, et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean J Anesthesiol. Dec 2015;68(6):547-555.
- Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reverted with neostigmine versus sugammadex. Minerva Anestesiol. Oct 16 2015.
- Pani N, Dongare PA, Mishra RK. Reversal agents in anaesthesia and critical care. Indian J Anaesth. Oct 2015;59(10):664-669.
- Plummer-Roberts AL, Trost C, Collins S, Hewer I. Residual Neuromuscular Blockade. AANA J. Feb 2016;84(1):57-65.
- Vymazal T, Krecmerova M, Bicek V, Lischke R. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery - a series of 117 cases. Ther Clin Risk Manag. 2015;11:1593-1596.
- Welliver M. New drug sugammadex a selective relaxant binding agent. AANA J. 2006;74(5):357-363.
- Welliver M, Cheek D. An update on sugammadex sodium. AANA J. 2009;77(3):219-228.
- Welliver M, Cheek D, Osterbrink J, McDonough J. Worldwide experience with sugammadex sodium: implications for the United States. AANA J. 2015;83(2):107-115
- Welliver M, McDonough J, Kalynych N, Redfern R. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. Drug Des Devel Ther. 2009;2:49-59.
- Yagan O, Karakahya RH, Tas N, Canakci E, Hanci V, Yurtlu BS. Intraocular pressure changes associated with tracheal extubation: Comparison of sugammadex with conventional reversal of neuromuscular blockade. J Pak Med Assoc. Nov 2015;65(11):1219-1225.
*Not an exhaustive literature list. For additional articles, visit the PubMed website.
The resources on this page may incorporate or summarize views, guidelines, or recommendations of third parties. Such material is assembled and presented in good faith, but does not necessarily reflect the views of the AANA. Links to third-party websites are inserted for informational purposes and do not constitute endorsement of the material on those sites, or of any associated organization.
Patients using hormonal contraceptives must use an additional, non-hormonal method of contraception for the next 7 days following sugammadex administration.